Trial Profile
Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Pharmacodynamics
- Acronyms RELAX
- Sponsors Abbott Laboratories; AbbVie
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Apr 2013 Planned End Date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 09 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.